Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial tags : Clinical-trials-phase-iii save search
Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity
Published: 2024-04-17 (Crawled : 11:00) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 1.03%
H: 1.66%
C: -1.11%
obesity tirzepatide
Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea & Vomiting at the Upcoming ASPAN 2024 National Conference in Orlando, Florida
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
EGRX | $4.38 -6.61% -7.08% 110K
|
Health Technology
|
| O: -8.14%
H: 19.55%
C: 18.18%
conference treatment pharmaceuticals for trial response
Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
MRNS | $1.45 20.83% 17.24% 10M
|
Health Technology
|
| O: -75.4%
H: 5.41%
C: -29.73%
first update pharmaceuticals trial financial results
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
Published: 2024-04-11 (Crawled : 23:00) - biospace.com/
TEVA | $13.18 0.69% 0.46% 6.6M
|
Health Technology
|
| O: -1.01%
H: 2.04%
C: 1.17%
ajovy for teva trial migraine china results
Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency
Published: 2024-04-03 (Crawled : 22:00) - biospace.com/
SNGX | $0.4963 5.15% -7.27% 4.2M
|
Health Technology
|
| O: -0.33%
H: 3.92%
C: -9.85%
design trial agreement
Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s Disease
Published: 2024-03-28 (Crawled : 22:00) - biospace.com/
BMY | $47.84 -0.87% -0.02% 12M
|
Health Technology
|
| O: 0.26%
H: 2.03%
C: 1.57%
first disease active update trial
Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
Published: 2024-03-26 (Crawled : 12:00) - biospace.com/
MRNA | News S | $103.45 -0.33% -0.33% 2M
|
Health Technology
|
| O: 1.29%
H: 0.0%
C: -3.93%
covid-19 vaccine positive trial results
FDA Rejects Regeneron’s Blood Cancer Therapy for Two Forms of Lymphoma
Published: 2024-03-25 (Crawled : 16:00) - biospace.com/
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: -100.0%
H: NaN%
C: Infinity%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: 0.42%
H: 0.0%
C: 0.0%
fda cancer blood therapy
Biophytis Presented its Phase 3 Protocol in the Treatment of Sarcopenia
Published: 2024-03-22 (Crawled : 08:00) - biospace.com/
BPTS | $0.2905 -17.38% 45K
|
Manufacturing
|
| O: -8.72%
H: 13.47%
C: 6.08%
treatment
Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer
Published: 2024-03-21 (Crawled : 12:00) - biospace.com/
MRK | $125.37 0.25% 0.1% 6.1M
|
Health Technology
|
| O: -0.13%
H: 0.4%
C: -0.06%
ylynk-006 keytruda lung merck update cancer cell trial plus
Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)
Published: 2024-03-19 (Crawled : 15:00) - biospace.com/
SEEL | $0.333 -13.53% -15.65% 720K
|
Health Technology
|
| O: -54.24%
H: 71.43%
C: 54.76%
sls-005 update sclerosis therapeutics results study
Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients
Published: 2024-03-19 (Crawled : 15:00) - biospace.com/
CERS | $1.63 -2.98% -3.07% 750K
|
Health Technology
|
| O: 12.9%
H: 5.71%
C: -2.86%
corporation positive blood system topline trial cardiovascular results
Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Published: 2024-03-12 (Crawled : 12:30) - biospace.com/
PFE A | $25.42 -1.05% -0.04% 44M
|
Health Technology
|
| O: -0.21%
H: 0.11%
C: -1.06%
adcetris positive trial
PureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in Japan
Published: 2024-02-27 (Crawled : 09:00) - biospace.com/
PTCHF | $2.78 19.97% 560
|
n/a
|
| O: -0.56%
H: 0.0%
C: -0.38%
AKLI | $0.2248 -12.54% 99K
|
|
| O: -3.85%
H: 12.67%
C: 6.92%
japan positive endeavorrx adhd trial results
Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in Japan
Published: 2024-02-26 (Crawled : 14:30) - biospace.com/
AKLI | $0.2248 -12.54% 99K
|
|
| O: 193.1%
H: 13.69%
C: -30.36%
endeavorrx japan positive adhd trial results
MANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA
Published: 2024-02-23 (Crawled : 21:00) - biospace.com/
AZN | $68.53 0.39% 0.39% 3.7M
|
Health Technology
|
| O: 1.29%
H: 1.49%
C: 1.34%
show
We Don’t Know What We Don’t Know: LGBTQIA+ Patient Data and the Struggle for Inclusivity
Published: 2024-02-22 (Crawled : 09:00) - biospace.com/
JNJ | News | $144.77 0.22% -0.01% 9.3M
|
Health Technology
|
| O: 0.59%
H: 1.11%
C: 0.92%
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 2.37%
H: 1.51%
C: 0.79%
Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
Published: 2024-02-20 (Crawled : 14:30) - biospace.com/
IMNM | $17.43 -5.27% -5.57% 950K
|
Health Technology
|
| O: -1.32%
H: 1.76%
C: -9.8%
al102 tumors study
KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
Published: 2024-02-16 (Crawled : 12:30) - biospace.com/
KALV | $11.67 -1.77% -1.8% 300K
|
Health Technology
|
| O: -0.68%
H: 2.32%
C: 1.36%
sebetralstat pharmaceuticals immunology meeting
AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease
Published: 2024-02-12 (Crawled : 19:00) - biospace.com/
ANTX | $2.48 0.41% 0.4% 87K
|
|
| O: -73.3%
H: 14.23%
C: -4.49%
lung disease trial
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.